BMS beats estimates, raises guidance

Bristol-Myers Squibb Co. (NYSE:BMY) reported 2Q16 financial results that beat estimates, and raised its EPS guidance for the year. Revenues in the quarter were $4.87 billion, up from $4.16 billion in 2Q15 and topping the $4.65 billion consensus estimate. Non-GAAP EPS in the quarter were $0.69, up from $0.53 in 2Q15 and edging out the $0.67 consensus.

BMS boosted its full-year 2016 non-GAAP EPS guidance to $2.55-$2.65 from $2.50-$2.60. ...